Quick Answer
Cogent Biosciences, Inc. reported Cash and Equivalents of $312.01 million for fiscal year 2025.
Cogent Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $312.01M | +217.8% |
| 2024 | $98.17M | +84.4% |
| 2023 | $53.23M | -61.9% |
| 2022 | $139.89M | -36.3% |
| 2021 | $219.68M | -9.3% |
| 2020 | $242.19M | +547.2% |
| 2019 | $37.42M | -32.8% |
| 2018 | $55.67M | +96.9% |
| 2017 | $28.27M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $125.30M | +29.1% | -1.8% |
| June 30, 2025 | $127.60M | +44.6% | +1.3% |
| March 31, 2025 | $126.00M | -41.6% | +28.4% |
| December 31, 2024 | $98.17M | +84.4% | +1.2% |
| September 30, 2024 | $97.05M | +11.8% | +10.0% |
| June 30, 2024 | $88.22M | -58.8% | -59.1% |
| March 31, 2024 | $215.80M | +34.3% | +305.4% |
| December 31, 2023 | $53.23M | -61.9% | -38.7% |
- Cogent Biosciences, Inc. showed an increase of +217.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Cogent Biosciences, Inc.’s cash and equivalents has grown by 1003.7% (from $28.27 million to $312.01 million).
- The most recent figure is from Cogent Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: